VKORC1 Inhibitors
1 drugsAbout VKORC1
Vitamin K epoxide reductase complex subunit 1 (VKORC1) is an enzyme in the vitamin K cycle, reducing vitamin K to its active form, essential for synthesizing coagulation factors.
VKORC1 is a key target for anticoagulant therapies in cardiovascular disease, though no genetic evidence directly links it to specific diseases.
VKORC1 is targeted by one FDA-approved drug, JANTOVEN, a small molecule used in cardiovascular applications since 2003.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Healthy Subjects with only 2 trials.
Top VKORC1 Drugs
UPSHER SMITH LABS is the only company with an approved drug targeting VKORC1.
The lack of competition suggests high barriers to entry or limited perceived market opportunity.
VKORC1 Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets VKORC1, using small molecule modality.
Exploring alternative modalities like antibodies or peptides could offer differentiation and new IP.
VKORC1 Clinical Trials 166 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 75 | 69 | 2 | 4 | 97% |
| Phase 2 | 19 | 13 | 5 | 1 | 72% |
| Phase 3 | 30 | 22 | 4 | 3 | 85% |
| Phase 4 | 42 | 26 | 6 | 10 | 81% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
VKORC1 Drug Approval Timeline (2003 - 2003)
JANTOVEN was first approved in 2003 and remains the only approved drug targeting VKORC1.
The stagnant approval timeline indicates a mature market with limited innovation in VKORC1-targeted therapies.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 105 clinical trials targeting VKORC1.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities